Does the media refer more to HYFT or IKT?

In the previous week, Inhibikase Therapeutics had 3 more articles in the media than MindWalk. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 5 mentions for MindWalk. Inhibikase Therapeutics' average media sentiment score of 0.81 beat MindWalk's score of 0.52 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer JMAC or HYFT?

MindWalk has a consensus target price of $5.00, indicating a potential upside of 254.61%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MindWalk 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has preferable valuation and earnings, JMAC or HYFT?

Maxpro Capital Acquisition has higher earnings, but lower revenue than MindWalk. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A MindWalk $17.59M 3.74 -$21.69M -$0.20 N/A

Which has stronger earnings and valuation, SRZN or HYFT?

MindWalk has higher revenue and earnings than Surrozen. MindWalk is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 69.23 -$242.03M -$37.59 N/A MindWalk $17.59M 3.74 -$21.69M -$0.20 N/A

Is SRZN or HYFT more profitable?

MindWalk has a net margin of -66.79% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% N/A -154.08% MindWalk -66.79% -69.37% -39.74%

Does the media favor SRZN or HYFT?

In the previous week, MindWalk had 1 more articles in the media than Surrozen. MarketBeat recorded 5 mentions for MindWalk and 4 mentions for Surrozen. Surrozen's average media sentiment score of 0.71 beat MindWalk's score of 0.52 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate HYFT or SIGA?

MindWalk presently has a consensus target price of $5.00, suggesting a potential upside of 254.61%. Given MindWalk's stronger consensus rating and higher possible upside, analysts plainly believe MindWalk is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MindWalk 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ACIU or HYFT?

MindWalk has higher revenue and earnings than AC Immune. MindWalk is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $4.31M 51.48 -$85.03M -$0.82 N/A MindWalk $17.59M 3.74 -$21.69M -$0.20 N/A

Is ACIU or HYFT more profitable?

MindWalk has a net margin of -66.79% compared to AC Immune's net margin of -1,788.02%. MindWalk's return on equity of -69.37% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% MindWalk -66.79% -69.37% -39.74%

MindWalk (HYFT) Competitors

$1.41 -0.08 (-5.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.44 +0.03 (+2.13%)

As of 07:57 PM Eastern

Compare

HYFT vs. IKT, JMAC, SRZN, SIGA, and ACIU

Should you buy MindWalk stock or one of its competitors? MarketBeat compares MindWalk with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MindWalk include Inhibikase Therapeutics (IKT), Maxpro Capital Acquisition (JMAC), Surrozen (SRZN), Siga Technologies (SIGA), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry.

How does MindWalk compare to Inhibikase Therapeutics?

MindWalk (NASDAQ:HYFT) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

MindWalk presently has a consensus target price of $5.00, indicating a potential upside of 254.61%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 168.66%. Given MindWalk's higher probable upside, equities research analysts clearly believe MindWalk is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MindWalk has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

In the previous week, Inhibikase Therapeutics had 3 more articles in the media than MindWalk. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 5 mentions for MindWalk. Inhibikase Therapeutics' average media sentiment score of 0.81 beat MindWalk's score of 0.52 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibikase Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibikase Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Inhibikase Therapeutics' return on equity of -41.31% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

MindWalk has higher revenue and earnings than Inhibikase Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	3.74	-$21.69M	-$0.20	N/A
Inhibikase Therapeutics	$260K	1,020.69	-$48.26M	-$0.43	N/A

Summary

Inhibikase Therapeutics beats MindWalk on 12 of the 17 factors compared between the two stocks.

How does MindWalk compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and MindWalk (NASDAQ:HYFT) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

MindWalk has a consensus target price of $5.00, indicating a potential upside of 254.61%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, MindWalk had 5 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 5 mentions for MindWalk and 0 mentions for Maxpro Capital Acquisition. MindWalk's average media sentiment score of 0.52 beat Maxpro Capital Acquisition's score of 0.00 indicating that MindWalk is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
MindWalk	Positive

Maxpro Capital Acquisition has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Maxpro Capital Acquisition's return on equity of 0.00% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
MindWalk	-66.79%	-69.37%	-39.74%

Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Maxpro Capital Acquisition has higher earnings, but lower revenue than MindWalk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MindWalk	$17.59M	3.74	-$21.69M	-$0.20	N/A

Summary

MindWalk beats Maxpro Capital Acquisition on 8 of the 13 factors compared between the two stocks.

How does MindWalk compare to Surrozen?

Surrozen (NASDAQ:SRZN) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

MindWalk has a net margin of -66.79% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	N/A	-154.08%
MindWalk	-66.79%	-69.37%	-39.74%

MindWalk has higher revenue and earnings than Surrozen. MindWalk is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	69.23	-$242.03M	-$37.59	N/A
MindWalk	$17.59M	3.74	-$21.69M	-$0.20	N/A

Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

66.6% of Surrozen shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Surrozen currently has a consensus price target of $42.00, suggesting a potential upside of 102.41%. MindWalk has a consensus price target of $5.00, suggesting a potential upside of 254.61%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, MindWalk had 1 more articles in the media than Surrozen. MarketBeat recorded 5 mentions for MindWalk and 4 mentions for Surrozen. Surrozen's average media sentiment score of 0.71 beat MindWalk's score of 0.52 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MindWalk beats Surrozen on 9 of the 16 factors compared between the two stocks.

How does MindWalk compare to Siga Technologies?

MindWalk (NASDAQ:HYFT) and Siga Technologies (NASDAQ:SIGA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

MindWalk has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

MindWalk presently has a consensus target price of $5.00, suggesting a potential upside of 254.61%. Given MindWalk's stronger consensus rating and higher possible upside, analysts plainly believe MindWalk is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 2.7% of Siga Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, MindWalk had 4 more articles in the media than Siga Technologies. MarketBeat recorded 5 mentions for MindWalk and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.93 beat MindWalk's score of 0.52 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
MindWalk	Positive
Siga Technologies	Positive

Siga Technologies has a net margin of 21.58% compared to MindWalk's net margin of -66.79%. Siga Technologies' return on equity of 10.60% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Siga Technologies	21.58%	10.60%	8.94%

Siga Technologies has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	3.74	-$21.69M	-$0.20	N/A
Siga Technologies	$94.57M	2.70	$23.28M	$0.27	13.19

Summary

Siga Technologies beats MindWalk on 10 of the 17 factors compared between the two stocks.

How does MindWalk compare to AC Immune?

AC Immune (NASDAQ:ACIU) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

51.4% of AC Immune shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MindWalk has higher revenue and earnings than AC Immune. MindWalk is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	51.48	-$85.03M	-$0.82	N/A
MindWalk	$17.59M	3.74	-$21.69M	-$0.20	N/A

In the previous week, MindWalk had 4 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for MindWalk and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.91 beat MindWalk's score of 0.52 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Very Positive
MindWalk	Positive

MindWalk has a net margin of -66.79% compared to AC Immune's net margin of -1,788.02%. MindWalk's return on equity of -69.37% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
MindWalk	-66.79%	-69.37%	-39.74%

AC Immune presently has a consensus price target of $7.50, suggesting a potential upside of 244.04%. MindWalk has a consensus price target of $5.00, suggesting a potential upside of 254.61%. Given MindWalk's stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

AC Immune has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Summary

MindWalk beats AC Immune on 11 of the 17 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYFT vs. The Competition

Export

Metric	MindWalk	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$69.60M	$942.35M	$5.09B	$12.66B
Dividend Yield	N/A	4.84%	34.29%	8.87%
P/E Ratio	-7.05	1.00	19.59	21.69
Price / Sales	3.74	113.16	132.64	89.74
Price / Cash	N/A	20.06	164.96	59.89
Price / Book	3.81	8.62	11.84	6.23
Net Income	-$21.69M	-$3.23M	$121.47M	$331.94M
7 Day Performance	-3.42%	-3.45%	-2.16%	-1.93%
1 Month Performance	-4.08%	-1.26%	-2.97%	-0.97%
1 Year Performance	N/A	36.92%	10.66%	18.24%

MindWalk Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYFT MindWalk	2.9538 of 5 stars	$1.41 -5.4%	$5.00 +254.6%	N/A	$69.60M	$17.59M	N/A	80
IKT Inhibikase Therapeutics	2.285 of 5 stars	$1.95 -4.7%	$5.40 +177.6%	N/A	$256.80M	$260K	N/A	6	News Coverage Analyst Upgrade
JMAC Maxpro Capital Acquisition	N/A	$19.11 +1.0%	N/A	+173.5%	$256.61M	N/A	N/A	2,021
SRZN Surrozen	3.1594 of 5 stars	$21.99 -6.4%	$42.00 +91.0%	+159.6%	$255.59M	$3.48M	N/A	80	News Coverage Short Interest Increase
SIGA Siga Technologies	0.6257 of 5 stars	$3.53 +0.7%	N/A	-46.9%	$252.81M	$94.57M	13.06	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYFT) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MindWalk (HYFT) Competitors

HYFT vs. IKT, JMAC, SRZN, SIGA, and ACIU

How does MindWalk compare to Inhibikase Therapeutics?

Summary

How does MindWalk compare to Maxpro Capital Acquisition?

Summary

How does MindWalk compare to Surrozen?

Summary

How does MindWalk compare to Siga Technologies?

Summary

How does MindWalk compare to AC Immune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MindWalk (HYFT) Competitors

HYFT vs. IKT, JMAC, SRZN, SIGA, and ACIU

How does MindWalk compare to Inhibikase Therapeutics?

Do analysts recommend HYFT or IKT?

Do institutionals and insiders believe in HYFT or IKT?

Which has more risk and volatility, HYFT or IKT?

Does the media refer more to HYFT or IKT?

Is HYFT or IKT more profitable?

Which has preferable earnings & valuation, HYFT or IKT?

Summary

How does MindWalk compare to Maxpro Capital Acquisition?

Do analysts prefer JMAC or HYFT?

Do institutionals & insiders have more ownership in JMAC or HYFT?

Does the media favor JMAC or HYFT?

Is JMAC or HYFT more profitable?

Which has more volatility & risk, JMAC or HYFT?

Which has preferable valuation and earnings, JMAC or HYFT?

Summary

How does MindWalk compare to Surrozen?

Is SRZN or HYFT more profitable?

Which has stronger earnings and valuation, SRZN or HYFT?

Which has more volatility & risk, SRZN or HYFT?

Do insiders & institutionals hold more shares of SRZN or HYFT?

Do analysts prefer SRZN or HYFT?

Does the media favor SRZN or HYFT?

Summary

How does MindWalk compare to Siga Technologies?

Which has more volatility & risk, HYFT or SIGA?

Do analysts rate HYFT or SIGA?

Do insiders and institutionals have more ownership in HYFT or SIGA?

Does the media refer more to HYFT or SIGA?

Is HYFT or SIGA more profitable?

Which has higher earnings & valuation, HYFT or SIGA?

Summary

How does MindWalk compare to AC Immune?

Do insiders & institutionals hold more shares of ACIU or HYFT?

Which has stronger earnings & valuation, ACIU or HYFT?

Does the media prefer ACIU or HYFT?

Is ACIU or HYFT more profitable?

Do analysts prefer ACIU or HYFT?

Which has more risk & volatility, ACIU or HYFT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools